This move is archived. Current quotes and coverage live on the stock page.
Get VM alerts:
A notable gain in Voyageur Pharmaceuticals Ltd stock signals investor optimism.
Voyageur Pharmaceuticals Ltd (VM.V) saw its share price rise by 7.14% in yesterday's trading session. This increase shows that investors are becoming more confident as the company enhances its operations and market presence.
Investor takeaway: Keep an eye on Voyageur's product offerings and market strategies, as these could impact future stock performance.
Advertisement
Voyageur Pharmaceuticals Ltd
VM.V
VM.V
Voyageur Pharmaceuticals Ltd
WealthAwesomeMarket cap
$37.35M
52W high
$0.20
52W low
$0.07
1W change
-2.94%
Beta
0.36
Analyst Price Targets
Based on analyst covering VM
Wall Street analysts forecast VM stock price to rise 233.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.55
+233.3% Upside
Current Price
C$0.17
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VM's historical volatility
30-Day Vol
55.2%
Annualized
90-Day Vol
82.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.18 | C$0.14 – C$0.21 |
| 60 trading days | C$0.19 | C$0.14 – C$0.24 |
| 90 trading days | C$0.20 | C$0.14 – C$0.27 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Voyageur Pharmaceuticals Ltd Market Cap Reaches CA$26 Million
With a market cap of CA$26 million, Voyageur occupies a niche market, but its profitability raises concerns for long-term investors.
Bull case
The recent start of commercial shipments of barium contrast products to Canadian clinics is a significant milestone for Voyageur. This development could lead to increased revenue and a larger market share.
Bear case
Despite the positive stock movement, investors should be cautious. The company has yet to report profits, and ongoing operational challenges may affect future performance.
Advertisement
Recent Developments Boost Confidence
Voyageur Pharmaceuticals Ltd's announcement about its first commercial shipments of barium contrast products has excited investors. Successfully delivering to a leading Canadian radiology provider not only demonstrates operational success but also opens up potential revenue streams. As the company navigates regulatory challenges, its ability to deliver on product promises will be key to keeping investors interested.
Market Response and Future Outlook
The 7.14% rise in Voyageur's stock price reflects a positive market reaction to its strategic initiatives. However, investors should remain cautious about the company's financial health, especially its current lack of profitability. The ongoing assessment of U.S. sites for a new manufacturing facility could improve production capabilities, but how well these plans are executed will be crucial for maintaining investor enthusiasm.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
